Abstracts tagged "Pulmonary Involvement"

Abstract Number: 034 • 2020 Pediatric Rheumatology Symposium
Chest Computed Tomography Manifestations in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Cohort Study
Pooja Patel¹, Gunes Orman ², Manuel Silva Carmona ³, Maria Pereira ⁴, Marietta De Guzman ⁵, Danielle Guffey ⁶, Scott Wenderfer ⁷ and R. Paul Guillerman ⁸, ¹Baylor College of Medicine, Houston, Texas, ²Edward B. Singleton Department of Radiology, Texas Children's Hospital, Houston, Texas, ³Section of Pulmonology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁵Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁶Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, ⁷Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁸Edward B. Singleton Department of Radiology, Texas Children's Hospital, Houston, Texas
Background/Purpose: Intrathoracic involvement in adults with systemic lupus erythematosus (SLE) is relatively common, particularly pleural disease. The prevalence of intrathoracic involvement in childhood-onset SLE (cSLE)…
Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Scott Matson¹, Kevin Deane ², Christopher Collora ¹, Xi Zheng ¹, Marie Fester ¹, Joyce Lee ¹ and M. Kristen Demoruelle ³, ¹University of Colorado, Denver, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Cosimo Bruni¹, Mariaelena Occhipinti ², Gianna Camiciottoli ³, Maurizio Bartolucci ⁴, Michael Pienn ⁵, Gemma Lepri ¹, Alessio Fabbrizzi ³, Alessandra Tottoli ¹, Giulia Ciardi ³, Dilia Giuggioli ⁶, Giovanna Cuomo ⁷, Francesco Masini ⁷, Andrea Olschewski ⁵, Federico Lavorini ³, Stefano Colagrande ⁸ and Marco Matucci-Cerinic ⁹, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Dept. Experimental and Clinical Medicine, Div. Pneumology and Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ³Dept. Experimental and Clinical Medicine, Div. Pneumology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁴Dept. of Services, Div. Emergency-Urgency Radiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ⁵Ludwig Boltzmann Institute for Lung Vascular Research, Institute of Physiology, Medical University of Graz, Graz, Austria, ⁶Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy, ⁸Dept. Experimental and Clinical Medicine, Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…
Abstract Number: 2615 • 2019 ACR/ARP Annual Meeting
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Tatiana Nevskaya ¹, Yuxuan Jiang ¹, Mianbo Wang ² and Janet Pope³, ¹University of Western Ontario, London, ON, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Western University, London, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared…
Abstract Number: 1421 • 2018 ACR/ARHP Annual Meeting
Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis
Oya Koker¹, Amra Adrovic², Sezgin Sahin², Kenan Barut², Rukiye Omeroglu³ and Ozgur Kasapcopur⁴, ¹Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ³Pediatric Rheumatology, Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Pulmonary vascular disease and interstitial lung fibrosis are the leading causes of morbidity and mortality in Juvenile Systemic Sclerosis (JSSc). Six-minute walk test (6MWT)…
Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Dinesh Khanna^1,2, Mary Strek³, Brian Southern⁴, Rajan Saggar⁵, Vivien Hsu⁶, Maureen D. Mayes⁷, Rick Silver⁸, Virginia D. Steen⁹, Donald Zoz¹⁰ and Franck Rahaghi¹¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Pulmonology, University of Chicago, Chicago, IL, ⁴Pulmonology, Cleveland Clinic Ohio, Cleavland, OH, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁸Rheumatology, Medical University of SC, Charleston, SC, ⁹Dept of Rheumatology, Georgetown Univ Medical Center, Washington, DC, ¹⁰Pulmonology, Boehringer Ingelheim, Ridgefield, CT, ¹¹Cleveland Clinic Florida Weston, Weston, FL
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…
Abstract Number: 1721 • 2018 ACR/ARHP Annual Meeting
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
Veronika K. Jaeger¹, Elise Siegert², Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci-Cerinic⁶, Oliver Distler⁷, Franco Cozzi⁸, Yannick Allanore⁹, Mangtao Li¹⁰, Mohammed Tikly¹¹ and Ulrich A. Walker¹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Second University of Naples, Naples, Italy, ⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁹Immunogenetics, Cochin Institute, Paris, France, ¹⁰Peking Union Medical College Hospital, Beijing, China, ¹¹Division of Rheumatology, Department of Internal Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Genetic and environmental factors play a significant role in SSc. African Americans are known for a higher SSc incidence, an earlier age of onset,…
Abstract Number: 1733 • 2018 ACR/ARHP Annual Meeting
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
Luis Valdés¹, Consuelo Orihuela-Sandoval², Liliana Muñoz-Hernández³, Miguel Ayala-León², José Luís Hernández-Oropeza⁴, Sergio Adán Benavides Suárez⁵, Alexia Esquinca-González⁵, Pablo Hernández-Reyes² and Tatiana S. Rodriguez-Reyna⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán., Mexico City, Mexico, ²Cardiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Endocrinology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Cardio-neumology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Prevalence of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is 8-12%, and 3-year survival rate is 47-56%. Rest echocardiogram is used to screen…
Abstract Number: 2214 • 2018 ACR/ARHP Annual Meeting
Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings
Janet Flores¹, Diego Baenas², Nadia Riscanevo³, Emanuel Saad⁴, Maria Jezabel Haye Salinas⁵, Soledad Retamozo⁶, Ana C. Alvarez⁵, Alejandro Alvarellos⁷, Juan Pablo Pirola⁸, Nadia Benzaquén⁵, Verónica Saurit⁹ and Francisco Caeiro⁸, ¹Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, ²Reumatologia, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Rheumatology, Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, ⁴Internal medicine, Hospital Privado, Cordoba, Argentina, ⁵Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁶Sociedad Argentina de Reumatologia, Córdoba, Argentina, ⁷Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina
Background/Purpose: Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease that affects exocrine glands. It can generate pulmonary compromise due to dysfunction of the glandular…
Abstract Number: 2261 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013
Patompong Ungprasert^1,2, Cynthia S. Crowson³, Eva M. Carmona Porquera⁴ and Eric L. Matteson⁵, ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Long-term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013 Background/Purpose: A hallmark of sarcoidosis is lung disease, which has variable expression. This study…
Abstract Number: 2422 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
Stephanie L. Giattino, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Currently published data regarding pregnancy outcomes in patients with interstitial lung disease (ILD) related to autoimmune disease and sarcoidosis is limited, with widely variant…
Abstract Number: 378 • 2018 ACR/ARHP Annual Meeting
Pulmonary Hypertension in Anti-Synthetase Syndrome
Chantelle Carneiro¹, Pichaya O-Charoen² and Soumya Chatterjee³, ¹Department of Internal Medicine, Cleveland Clinic, Cleveland Heights, OH, ²Department of Medicine - Division of Allergy, Immunology and Rheumatology, Mahidol University, Bangkok, Thailand, ³Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical manifestations of anti-synthetase syndrome (ASS) include fever, Raynaud phenomenon, mechanic’s hands, inflammatory arthritis, myositis and interstitial lung disease (ILD). Pulmonary hypertension (PH), although…
Abstract Number: 787 • 2018 ACR/ARHP Annual Meeting
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
Maaike Boonstra¹, Maarten K. Ninaber², Nina Ajmone Marsan³, Hans U. Scherer¹, Tom W.J. Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Heart and Lung Center; Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ³Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: SSc is known for its heterogeneous disease course in which anti-topoisomerase I antibodies (ATA) are associated with dcSSc and interstitial lung disease and therefore…
Abstract Number: 795 • 2018 ACR/ARHP Annual Meeting
Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort
Kristina E.N. Clark¹, Corrado Campochiaro², Lauren V. Host³, Alper Sari⁴, Svetlana I. Nihtyanova⁵, Carmen Fonseca⁶, Christopher P. Denton⁷ and Voon H. Ong⁸, ¹Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁶UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are characterised by specific autoantibodies which are useful for diagnosis. Rare antibodies have been described in CTDs in several case…
Abstract Number: 1109 • 2018 ACR/ARHP Annual Meeting
Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis
Yoshinobu Koyama¹, Soichiro Fuke², Takashi Ohno³, Yoshiharu Sato⁴ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³Management of medical safety, Okayama University Hospital, Okayama, Japan, ⁴DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].